Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Fighting fat with a single molecule

01.08.2014

A single molecule may provide hope for millions of people, as researchers have combined two hormones formed in the digestive tract into one novel molecule.

This hormone combination acts on the receptors of insulin-stimulating hormones and is thus able to reduce blood sugar levels in patients suffering from obesity or type 2 diabetes.

In the coming years, this new therapeutic approach could help successfully treat both of these diseases, which the United Nations and the World Health Organization count among the greatest medical challenges facing modern society.

For their ground-breaking research, a team of chemists, pharmacologists and hormone and cancer researchers led by Matthias Tschöp, director of Helmholtz Zentrum München and professor at Technische Universität München (TUM), has received the 2014 Erwin Schrödinger Prize, an interdisciplinary research award that includes €50,000 in prize money.

This completely new single-molecule hormone combination leads to effective weight loss and improved blood sugar in animal models. The two hormones employed, GLP-1 and GIP, originate in the human digestive tract, where they control food intake and various metabolic processes. When sugar is ingested, the combined hormone the researchers have created causes an increased release of insulin; it also functions as an appetite suppressant and increases fat-burning processes.

The findings of the research team, which included Matthias Tschöp, Brian Finan, Kerstin Stemmer (all of the Institute for Diabetes and Obesity at the Helmholtz Zentrum München) and Richard DiMarchi (Indiana University, USA), were able to prove that metabolic regulation in the brain can be influenced via natural gut hormones. Should further scientific and clinical tests confirm this, then this approach will represent a breakthrough in diabetes prevention and therapy. This could result in the establishment of new therapeutic concepts for metabolic disorders.

However, not all hope hinges on one agent alone. In the meantime, the interdisciplinary researcher team has identified a series of combined agents. These include combinations of GLP-1 and glucagon as well as GLP-1-based conjugates that deliver steroid hormones such as oestrogen only to cells affecting metabolism, yet not to cells that could suffer from side effects.

The discovery and successful development of such new pharmacological compounds is especially important due to the fact that, despite the almost-epidemic spread of obesity and type-2 diabetes among the general populace in recent years, almost no new pharmacology-based therapeutic approach to treatment has yet been developed.

Although it will be some time until it can be employed as an approved therapy method, this new multifunctional agent approach would offer the possibility of designing personalised therapies to treat people suffering from type-2 diabetes.

“This award shows how important research in the field of metabolic disorders is to modern society,” says Jürgen Mlynek, President of the Helmholtz Association. “The mission of the Helmholtz Association is to find solutions to problems facing society through our basic research.” Mlynek will present the Erwin Schrödinger Prize on 18 September 2014 at the Helmholtz Annual Meeting in Berlin.

The award recipients:

Prof. Matthias Tschöp, Institute for Diabetes and Obesity, Helmholtz Zentrum München – German Research Center for Environmental Health and the Technische Universität München

Prof. Richard DiMarchi, Standiford H. Cox Distinguished Professor of Chemistry, Linda & Jack Gill Chair in Biomolecular Sciences, Department of Chemistry, Indiana University

Dr Kerstin Stemmer, Division of Metabolism and Cancer, Institute for Diabetes and Obesity, Helmholtz Zentrum München – German Research Center for Environmental Health

Dr Brian Finan, Division of Molecular Pharmacology, Institute for Diabetes and Obesity, Helmholtz Zentrum München – German Research Center for Environmental Health

The Erwin Schrödinger Prize
Since 1999, the Helmholtz Association and the Stifterverband – Erwin Schrödinger Prize honours outstanding and innovative scientific and technological achievements realised on the frontiers of various disciplines in medicine, the natural sciences and engineering. Representatives from at least two disciplines have to have been involved in the research effort. The prize money is supplied by the Stifterverband one year and the Helmholtz Association the next. The prize winners can use the €50,000 in prize money as they please.

The Helmholtz Association contributes to solving major challenges facing society, science and the economy with top scientific achievements in six research fields: Energy, Earth and Environment, Health, Key Technologies, Structure of Matter, Aeronautics, Space and Transport. With 36.000 employees in 18 research centres and an annual budget of approximately 3.8 billion euros, the Helmholtz Association is Germany’s largest scientific organisation. Its work follows in the tradition of the great natural scientist Hermann von Helmholtz (1821-1894).

Contacts for the Media:

Prof. Dr Angela Bittner
Press Officer Coummunications and Media
Tel.: +49 (30) 206 329-54
angela.bittner@helmholtz.de


Helmholtz Association
Office Berlin
Anna-Louisa-Karsch-Str. 2
10178 Berlin
Germany

Weitere Informationen:

http://www.helmholtz.de
http://www.helmholtz.de/socialmedia

Jan-Martin Wiarda | Helmholtz-Gemeinschaft

Further reports about: Diabetes Fighting Health Schrödinger blood disorders hormone metabolic natural sugar

More articles from Awards Funding:

nachricht RNA: a vicious pathway to cancer ?
14.08.2017 | Goethe-Universität Frankfurt am Main

nachricht Extensive Funding for Research on Chromatin, Adrenal Gland, and Cancer Therapy
28.06.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

All articles from Awards Funding >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Nagoya physicists resolve long-standing mystery of structure-less transition

21.08.2017 | Materials Sciences

Chronic stress induces fatal organ dysfunctions via a new neural circuit

21.08.2017 | Health and Medicine

Scientists from the MSU studied new liquid-crystalline photochrom

21.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>